Systems Pharmacology Study of the Anticervical Cancer Mechanisms of FDY003

Abstract

Increasing data support that herbal medicines are beneficial in the treatment of cervical cancer; however, their mechanisms of action remain to be elucidated. In the current study, we used a systems pharmacology approach to explore the pharmacological mechanisms of FDY003, an anticancer herbal formula comprising Lonicera japonica Thunberg, Artemisia capillaris Thunberg, and Cordyceps militaris (Linn.) Link, in the treatment of cervical cancer. Through the pharmacokinetic assessment of absorption-distribution-metabolism-excretion characteristics, we found 18 active compounds that might interact with 106 cervical cancer-related targets responsible for the pharmacological effects. FDY003 targets were significantly associated with gene ontology terms related to the regulation of cellular behaviors, including cell proliferation, cell cycle processes, cell migration, cell apoptosis, cell death, and angiogenesis. The therapeutic targets of the herbal drug were further enriched in various oncogenic pathways that are implicated in the tumorigenesis and progression of cervical cancer, including the phosphatidylinositol 3-kinase, mitogen-activated protein kinase, focal adhesion, human papillomavirus infection, and tumor necrosis factor signaling pathways. Our study provides a systematic approach to explore the anticancer properties of herbal medicines against cervical cancer.

A Network Pharmacology Perspective Investigation of the Pharmacological Mechanisms of the Herbal Drug FDY003 in Gastric Cancer

“…Although the application of herbal drugs for GC treatment has gained increasing attention [5][6][7][8] , their complex multicomponentmultitarget mechanistic properties have yet to be investigated. In this study, we dissected the anti-GC properties of the herbal drug FDY003 through a systems perspective [9][10][11] . We found that FDY003 suppressed the viability and enhanced the chemosensitivity of human GC cells.…”

“…FDY003 is an anticancer herbal drug composed of Cordyceps militaris (Cm), Artemisia capillaris Thunberg (AcT), and Lonicera japonica Thunberg (LjT) [9][10][11] . It suppresses growth and promotes apoptosis in various cancers by targeting crucial genes and proteins associated with cancerous behaviors [9][10][11] . However, the anticancer effects of FDY003 on GC and the mechanisms involved need to be elucidated.…”

Exploration of the System-Level Mechanisms of the Herbal Drug FDY003 for Pancreatic Cancer Treatment: A Network Pharmacological Investigation

“…FDY003, which is made up of Lonicera japonica Thunberg (LjT), Cordyceps militaris (Cm), and Artemisia capillaris Thunberg (AcT), is an herbal drug that exerts anticancer activity [ 9 – 11 ]. This herbal drug has antiproliferative and apoptosis-promoting properties in a variety of cancer types by pharmacologically modulating cancer-associated genes and proteins that regulate and promote key protumorigenic cellular processes [ 9 – 11 ]. However, the anti-PC potential of FDY003 and the underlying mechanisms remain to be investigated.…”

A Network Pharmacological Elucidation of the Systematic Treatment Activities and Mechanisms of the Herbal Drug FDY003 Against Esophageal Cancer

“…3,4 FDY003-an herbal mixture made up of Artemisia capillaris Thunberg (AcT), Cordyceps militaris (Linnaeus) Link (Cm), and Lonicera japonica Thunberg (LjT)-has been developed for cancer treatment and effectively triggers growth arrest and apoptosis in cancer cells. [5][6][7][8] This herbal drug exhibits a multiple compound-multiple target-multiple pathway mechanism of action by regulating various crucial cancer-associated gene, proteins, and pathways to exert its anticancer effects and to act as a chemosensitizer. [5][6][7][8] However, the pharmacological roles and regulatory mechanisms of FDY003 in EC have not been evaluated.…”

“…[5][6][7][8] This herbal drug exhibits a multiple compound-multiple target-multiple pathway mechanism of action by regulating various crucial cancer-associated gene, proteins, and pathways to exert its anticancer effects and to act as a chemosensitizer. [5][6][7][8] However, the pharmacological roles and regulatory mechanisms of FDY003 in EC have not been evaluated.…”